Scalper1 News
Before the Q1 earnings reports start rolling in next month, likely the biggest mover of biotech and pharma stocks will be releases of clinical-trial data. Here are four such reports expected this month and what the Street expects from them. Probably the most anticipated is Biogen Idec’s (BIIB) presentation of phase one results on its Alzheimer’s disease drug BIIB-037 this Friday. Last week, RBC Capital Markets made the bull case for the drug, Scalper1 News
Scalper1 News